stockrow
Friday 6 November 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +200.5%
Quarter to September 2026, against a year earlier
12.19
1.17
+10.62%
Follow VIR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 5 | 5 |
| (45.73%) | (47.69%) | (26.08%) | (21.84%) | ||
| (36.47%) | (37.95%) | (20.91%) | (17.34%) | ||
ROIC |
(101.09%) | (88.19%) | (39.10%) | (30.32%) | |
Return on Tangible Assets |
(91.84%) | (88.09%) | (47.56%) | (38.87%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.86) | (3.05) | (1.21) | (0.84) | |
Free Cash Flow |
(396.36) | (449.67) | (203.67) | (141.93) | |
Capital Expenditures |
(4.58) | (3.62) | (1.16) | (0.91) | |
| Other line items | |||||
Cash ROIC |
(32.11%) | (34.83%) | (13.42%) | (10.46%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.10 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
5,039.57 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | — | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
665.10% | 681.34% | 159.62% | 136.26% | |
Selling, General and Administrative Expense of Revenue |
134.30% | 139.66% | 32.77% | 33.55% | |
Share Based Compensation of Revenue |
71.58% | 71.91% | 15.51% | 15.24% | |
Operating CF/Net income |
0.89 | 1.01 | 0.80 | 0.76 | |
Depreciation/Fixed assets |
0.38 | 0.33 | 0.30 | 0.27 | |
Capex/Depreciation |
(0.22) | (0.21) | (0.08) | (0.07) | |
Revenue per Share |
0.49 | 0.44 | 1.81 | 1.79 | |
Operating CF per Share |
(2.83) | (3.03) | (1.21) | (0.83) | |
Capex per Share |
(0.03) | (0.02) | (0.01) | (0.01) | |
Capex to Sales |
0.07 | 0.06 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026